Professor Mark Bellis, OBE
Mark is Director of the Centre for Public Health at Liverpool John Moores University, a World Health Organization (WHO) Collaborating Centre for Violence Prevention. He also directs the North West Public Health Observatory, the lead UK Observatory for public health intelligence on alcohol, drugs and violence. Currently, Mark sits on the advisory group for the World Health Organization’s European alcohol strategy and is also on the advisory board for injury and violence prevention to the Director General of WHO. Mark has acted as expert advisor on substance use, sexual health and violence prevention to many organisations including the United Nations, Council of Europe, European Public Health Alliance and the European Monitoring Centre for Drugs and Drug Addiction.
Professor Tim Cable
Tim is Director of the School of Sport and Exercise Sciences at LJMU and is responsible for the management of this dynamic research and teaching environment. Tim’s specific area of research focus is exercise ageing and the cardiovascular system and cardiovascular control. To date he has published more than 116 peer-review articles in international journals (50 since 2007), procured £7.3m in research and enterprise funding and supervised 35 PhD completions. He also has a strong interest in developing curricula that promote employment prospects for students and has received a number of major awards to support this activity including a successful application for Centre of Excellence in Teaching and Learning status and a National Teaching Fellowship.
Simon Constable, BSc, MBBS, MRCP(UK)
Honorary Senior Lecturer in Clinical Pharmacology & Therapeutics, the University of Liverpool
Simon is the Divisional Medical Director for the Division of Medicine and a Consultant Physician in Acute Medicine at the Royal Liverpool and Broadgreen University Hospitals NHS Trust and Honorary Senior Lecturer in Clinical Pharmacology & Therapeutics at the University of Liverpool. He studied medicine at Guy’s and St Thomas’ Hospitals Medical School in London and following a period of post-graduate basic medical and specialist training in the UK and New Zealand was appointed a Lecturer in Clinical Pharmacology at the University of Liverpool. He has worked in the NHS, academia and pharmaceutical industry and, before being appointed to his current role at RLBUHT, was Vice President and Medical Director of a global early-phase clinical trials contract research organization.
His current role within the Division of Medicine’s management team also allows a continued interest in undergraduate teaching (mainly on pharmacological topics) and in early phase clinical trials, working with Research, Development and Innovation.
Professor Andrew Cossins
Andrew is Head of the Institute of Integrative Biology at the University of Liverpool. Previous to this he has led the Consortium for Post-Genome Science, a large cross-disciplinary research programme directed at generating a strong genomics capability in the North West Region. This incorporated the Centre for BioArray Innovation of which he was Director, which linked colleagues in chemistry, mathematics and engineering with biosciences. Currently, Andrew is a co-Director for the Centre for Genome Research, and is a member of the Board of Director for the Company of Biologists, a research charity that supports research and study across all branches of biology. In recent years Andrew has been funded by MRC, NERC, BBSRC, EC, Shell Global and Syngenta.
Professor James Ford
Jim is Director of the School of Pharmacy at Liverpool John Moores University, a post he has held since 2004. Jim’s association with the School spans over 35 years; he joined the School as a postgraduate student in 1975 and was appointed Professor of Pharmaceutics in 1995. Jim is a Fellow of both the Royal Society of Chemistry and the Royal Pharmaceutical Society. Jim’s main research interests include children’s medicines; solid dispersion techniques; thermal analysis of drugs, pharmaceutical excipients and polymers; cellulose ethers in extended-release matrices; controlled release from coated pellets and matrices; effects of modifications of crystal habits and polymorphs on their compression properties.
He is an Advisory Board member of the Cheshire, Merseyside and North Wales Medicines for Children Local Research Network and member of the advisory committee of the Network’s Formulation Subgroup of the Pharmacy and Pharmacology Clinical Studies Group. The Network has a remit to support the national research network to undertake important clinical studies into the safety and effectiveness of medicines for children.
Professor Neil Hall, BSc, PhD
Neil is Professor of Genomics at the University of Liverpool. He runs a research lab that focuses on pathogen genomics. He is also is Director of the Centre for Genomic Research which is a national facility for Medical and Environmental researchers. He has previously been a group leader at the Sanger Institute in Cambridge and at the Institute for Genomic Research in Maryland. Neil did his PhD and BSc at The University of Liverpool. He is currently funded by the BBSRC, MRC, The Royal Society and The Wellcome Trust. He also collaborates with a number of local companies.
Professor Simon Harding, MB ChB, FRCS, FRCOphth, MD
Honorary Consultant Ophthalmologist, Royal Liverpool & Broadgreen University Hospitals NHS Trust
Head of the Department of Eye and Vision Science, the University of Liverpool
Simon has led the development of the early detection and medical management of retinal diseases locally, nationally and internationally, particularly in relation to diabetic retinopathy and age-related macular degeneration (AMD). He has ongoing research programmes in diabetic eye disease (screening, early detection, treatment), AMD (new therapies), retinal structure and function (image analysis, electrophysiology, blood flow) and cerebral malaria (malarial retinopathy) having written or contributed to 96 peer reviewed publications and leading/collaborating in grants totalling nearly £11 million.
He set up and chairs a local charity, The Foundation for the Prevention of Blindness, which supports local eye research and commissioned a purpose-built clinical trial centre, the Clinical Eye Research Centre, opened in 2006 and greatly expanding clinical research in Liverpool.
In 2008 he took up the newly created Chair of Clinical Ophthalmology with the exciting role of leading clinical eye research in Liverpool and further developing links across disciplines and organisations within the University and NHS. In August 2010 he was appointed Head of the newly created Department of Eye and Vision Science.
Professor Janet Hemingway, BSc, PhD, FMedSci, HonFRCP
Janet initially trained as a geneticist and is currently Professor of Insect Molecular Biology and Director of the Liverpool School of Tropical Medicine, the world’s oldest tropical medical institution.She has 30 years’ experience working on the biochemistry and molecular biology of specific enzyme systems associated with xenobiotic resistance and is PI on several projects worldwide worth well in excess of £30 million.
She was awarded the prestigious UK Industry Academe prize in 1993 by the UK Prime Minister and Department of Trade and Industry for her productive work with the pesticide industry. She was inaugurated as a Fellow of the Academy of Medical Sciences in 2006, a Fellow of the Royal College of Physicians in 2008, conferred as Honorary Doctor of Science by Sheffield University in 2009 and was elected to the US National Academy of Sciences as a foreign associate for her excellence in original scientific research in 2010.
Helen has lead responsibility at the Royal Liverpool and Broadgreen University Hospitals NHS Trust for the biocampus, strategy development, sustainability and the new hospital. She has degrees from Aberdeen University and Imperial College and has previously worked for the World Health Organisation, Department of Health, in the private sector and at Central Manchester Foundation Trust.
Aidan was appointed in 2012, joining the Trust from Blackpool Teaching Hospitals NHS Foundation Trust where he had been Chief Executive since 2009. He has over twenty years’ NHS experience and is a fully qualified Chartered Accountant. After NHS management training and a six-year spell working with KPMG, he returned to the health service and held senior roles at University Hospitals Birmingham and Salford Royal Hospitals. Aidan has also worked as Director of Operations and Deputy Chief Executive at Blackpool.
Professor Saye Khoo, MD, MRCP, DTM&H
Honorary Consultant Physician in Infectious Diseases, Royal Liverpool & Broadgreen University Hospitals NHS Trust
Saye is a Consultant in Infectious Diseases, and Professor in the Department of Pharmacology, Institute of Translational Medicine. He leads a Bioanalytical Facility for Drugs and Small Molecules which is GCLP-accredited. Research outputs have included establishment of therapeutic drug monitoring for HIV drugs as standard of care in the UK, and an HIV drug interactions website (www.hiv-druginteractions.org) which serves as a primary resource for treatment guidelines in over 15 countries in Europe, the Americas, Asia and Australasia.
Current projects also include work characterising factors increasing susceptibility to HIV treatment failure such as pregnancy, children, pharmacogenetic differences, adherence and drug interactions.
Professor Martin Lombard, MB, BCh, BAO, MD, MSc, FRCPI, FRCP
National Clinical Director for Liver Disease at the Department of Health
Martin qualified from University College Dublin in 1980 and trained in Medicine and Gastroenterology in Dublin and in Hepatology at Kings College Hospital in London before taking up a consultant and senior lecturer appointment in 1990 in Liverpool where he is currently a Consultant Hepatologist and Gastroenterologist at the Royal Liverpool University Hospital. He has held positions of Clinical Director of Gastroenterology in two University hospitals over 10 years and Regional Training Programme Director for Gastroenterology for 10 years, Chairman of the British Society of Gastroenterology Training Committee for 3 years, Chairman regional cancer network for 4 years and in 2010 was appointed the first National Clinical Director for Liver Disease at the Department of Health. He has pioneered pancreato-biliary EUS in the UK and has been involved in measuring and setting national performance standards in ERCP through the British Society of Gastroenterology. He is Chairman of the regional cancer network group for liver and pancreas. He has an extensive publication record in Liver and HPB disorders.
Sir Howard Newby, KB, CBE, BA, PhD, AcSS
Sir Howard was previously Vice-Chancellor of the University of the West of England (UWE) in Bristol having also spent five years as the Chief Executive of the Higher Education Funding Council for England (HEFCE). He was Vice-Chancellor of the University of Southampton from 1994 to 2001 and was previously Chairman and Chief Executive of the Economic and Social Research Council (ESRC). From 1999 to 2001, Sir Howard was President of Universities UK, the UK body which represents the university sector. He was also President of the British Association for the Advancement of Science for 2001-2002. He was made a CBE in 1995 for services to social science and a knighthood in 2000 for services to higher education.
Sir Howard was formerly a Professor of Sociology in both the UK and USA and has published a large number of books and articles on social change in rural England. He has a lifelong interest in railway history and is currently a member of the Railway Heritage Committee, a Board member of the National Railway Museum and a Trustee of the National Museum of Science and Industry. He is a governor of the British Film Institute. He is also a Trustee of the National Football Museum and a lifelong supporter of Derby County Football Club.
Since he arrived at the University, Sir Howard has instituted a new strategic plan and been active in driving forward the University at the heart of the regional knowledge economy.
Professor Andrew Pettitt, MA, MB BChir, PhD, MRCP, FRCPath
Honorary Consultant Haematologist, the Royal Liverpool & Broadgreen University Hospitals NHS Trust
Andrew is Head of the Department of Molecular and Clinical Cancer Medicine at the University of Liverpool and an Honorary Consultant Haematologist at the Royal Liverpool University Hospital. He is an internationally recognised expert in chronic lymphocytic leukaemia (CLL) and related disorders and leads a large (>£6M) programme of clinical and translational research which includes being Chief Investigator for three current national clinical trials. Other leadership roles include being Director of UK CLL Trials Biobank (which he founded in 2008 to support translational research at national level) and Chair of the National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group.
Professor Munir Piromohamed, MB ChB (Hons), MRCP, PhD, FRCP, FRCP(E), FBPhamacolS
Munir was appointed Consultant Physician at the Trust in 1996. He was awarded a Personal Chair in Clinical Pharmacology at the University of Liverpool in 2001, and in 2007, was appointed to the NHS Chair of Pharmacogenetics. He is also Deputy Director of the MRC Centre for Drug Safety Sciences in Liverpool and a member of the Commission on Human Medicines and Chair of its Pharmacovigilance Expert Advisory Group.
His main area of research is in pharmacogenetics and drug safety. Adverse reactions to drugs are a major cause of illness in the population. The research aims to maximise the benefits of drugs and minimize their harms. This is being achieved through the use of different strategies ranging from improvements in prescribing to the development of genetic and other tests for predicting and monitoring individual susceptibility to toxicity.
Professor Robert Sutton, DPhil FRCS
Director of Research, Development & Innovation, Royal Liverpool & Broadgreen University Hospitals NHS Trust
Professor of Surgery, Institute of Translational Medicine, the University of Liverpool
Robert is Professor of Surgery in the Institute of Translational Medicine at the University of Liverpool and Honorary Consultant Surgeon at the Royal Liverpool and Broadgreen University Hospitals NHS Trust, Executive Director of the Liverpool NIHR Pancreas Biomedical Research Unit and Director of Research, Development & Innovation at the Royal Liverpool and Broadgreen University Hospitals NHS Trust.
His clinical practice and research interests are in the pathophysiology and management of acute and chronic pancreatitis, and in pancreatic neoplasia. He is committed to the development of a comprehensive translational research platform for the development of new drugs and diagnostics in pancreatic digestive diseases, a major theme in the University’s Institute of Translational Medicine and RLBUHT.
Current advisory work includes Research Awards Committee, CORE (Digestive Disorders Foundation); Pancreatic Section Committee, British Society of Gastroenterology; Research Committee, British Society of Gastroenterology; Executive Committee, Pancreatic Society of GB&I; Editorial Board, Cochrane Hepatobiliary Review Group; Editorial Board, Digestive Surgery; Editorial Board, World Journal of Gastroenterology; Council, European Digestive Surgery; Faculty, American Pancreatic Association; Faculty and Organising Committee, European Pancreatic Club; Organising Committee and Council, International Association of Pancreatology.
Professor Cheng-Hock Toh, MB, ChB (Hons), MD, FRCP (Lon), FRCPath
Cheng-Hock is Director of the NIHR Biomedical Research Centre Liverpool. The Centre specialises in Microbial Diseases and is a joint-partnership between the Royal Liverpool and Broadgreen University Hospitals NHS Trust, the University of Liverpool and the Liverpool School of Tropical Medicine. With a background in haematology, this highly translational clinical specialty has fostered his research interest in infection-related blood coagulation problems. Internationally renowned in the field of disseminated intravascular coagulation, Professor Toh has been honoured by his peers as President-elect of the International Society on Thrombosis and Haemostasis Scientific & Standardization Committee meeting in 2012.
Geoff graduated from University with a PhD in Biochemistry. After working for a large contract research organisation, servicing clients such as AstraZeneca, NutraSweet and Unilever, and post-doctoral research work, Geoff joined MerseyBIO in 2001. In this role, Geoff was responsible for the design of the facility, development of its business and operational models, and marketing of the Incubator.
The MerseyBIO Incubator became operational in March 2003, and in that time has attracted 38 new start-up life science companies covering a diverse range of business type and model. In 2005 and 2006, two of the Incubator companies listed on the AIM stock market. In late 2005, Geoff’s role expanded to become Sector Director for Life Sciences for Merseyside, which drew in a wider role engaging the business community and stakeholders in the local cluster and becoming their ‘voice of the industry’ relating to the public sector support agencies and programmes. In 2007, Geoff and his co-Director Rhys Roberts, spun-out the MerseyBIO operation in to a new company, 2Bio Ltd.
2Bio Ltd has grown its business to provide services to support the development of early-stage technologies of its clients and facilities to house life science companies – which include – investors, research organisations, government economic agencies and companies in Europe, Australasia, North America and South East Asia.